[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349477-105":59,"doc-detail-349477-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","perspective-on-lessons-not-learned-from-coleys-toxins-to-microbial-drug-delivery-guidance-for-institutional-review-boards-irbs","Perspective on Lessons Not Learned: From Coley’s Toxins to Microbial Drug Delivery - Guidance for Institutional Review Boards (IRBs)","","The bacterial and toxin approach to cancer therapy traces back 130 years and relies on nonspecific bacterial-toxin-generated immunotherapy. High-risk oncology research is now re-emerging, with glioblastomas and other resistant cancers serving as a modern testbed following sepsis-associated remission. The perspective reviews protocols IRBs should consider for live bacterial or synthetic immuno-stimulatory trials, emphasizing human-specific SIGLEC-13&17 control of TLR-4 signaling and its impact on endotoxin sensitivity, animal-model interpretation, and risk planning.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/perspective-on-lessons-not-learned-from-coleys-toxins-to-microbial-drug-delivery-guidance-for-institutional-review-boards-irbs/349477/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/perspective-on-lessons-not-learned-from-coleys-toxins-to-microbial-drug-delivery-guidance-for-institutional-review-boards-irbs/349477.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do the authors focus on glioblastoma in this perspective?","Question",{"text":112,"@type":113},"Glioblastoma is described as highly resistant with low survival and few therapeutic options, making it a central focus for exploring bacterial and toxin-based approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What guidance does the paper propose for institutional review boards (IRBs)?",{"text":117,"@type":113},"It outlines protocols IRBs should consider for live bacterial or synthetic immuno-stimulatory trials, especially to protect patient safety when sepsis or cytokine storm risk exists.",{"name":119,"@type":110,"acceptedAnswer":120},"How do SIGLEC-13&17 and TLR-4 signaling affect interpretation of trial results?",{"text":121,"@type":113},"The authors argue that human SIGLEC-13&17 uniquely modulate excessive TLR-4 signaling and that humans are far more sensitive to LPS/endotoxin than mice and rats, affecting how animal model results translate to humans.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349477,1791355916,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Perspective  \nPerspective on Lessons Not Learned: From Coley’s Toxins to Microbial Drug Delivery, Guidance for Institutional Review Boards (IRBs)  \nBrian P. Hanley 1,*, Alejandro J. Betancourt 1,2, Gustavo Gross 1 and Wilbur (Bo) Bowne 1  \nAcademic Editor: Antonio Di Stefano  \nReceived: 23 May 2026  \nRevised: 28 June 2026  \nAccepted: 29 June 2026  \nPublished: 3 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 UTRGV Department of Surgery, UTRGV School of Medicine, 1210 W. Schunior St., Edinburg, TX 78541, USA  \n2 Neurosurgery, Valley Baptist Medical Center, 1040 W. Jefferson St., Brownsville, TX 78520, USA  \n* [Correspondence: brian.hanley@utrgv.edu](Correspondence: brian.hanley@utrgv.edu)  \nAbstract  \nThe bacterial and toxin methods of cancer treatment date back 130 years. This paradigm rests on nonspecific bacterial-toxin-generated immunotherapy. This high-risk oncology research is experiencing a renaissance of methods that are among the most effective yet. Glioblastomas and other resistant cancers are the modern touchpoint, because of remission history following sepsis. Spurred by recent research deaths, we discuss protocols IRBs should consider in live bacterial or synthetic immuno-stimulatory trials. Human systemic inflammatory response syndrome immunology is unique due to non-functioning SIGLEC- 13 and 17, which control excessive Toll-like receptor 4 (TLR-4) signaling. This is not a technicality like human CD8+/CD4+ T cells. SIGLEC-13&17 consequences are profound; humans are ≈330–200,000 times more sensitive to LPS/endotoxin than mice and rats. This human TLR-4 difference also applies to gene therapy and should inform the results from any animal model, including non-human primates. Clinical TLR-4 stimulation takes two forms: bacterial infection and sterile TLR-4 stimulators, and treatments differ. The stereotactic injection of calculated amounts of adjuvants like endotoxin, venoms/components, or synthetic alternatives maybe safer than live bacteria. Inadequate planning for risk elements, basic predictive models, and treatments will likely cause death.  \nKeywords: brain neoplasms; glioma; tumors; brain tumors; sepsis; septicemia; bacterial cancer treatment; institutional review board; Coley’s toxins  \n1. Introduction  \n“. . .bacterial-based therapies far outperform more traditional methods. [for resistant cancers]” Meng et al. [1]  \nThere is a renaissance in bacterial=based therapies for resistant cancers [1] . Consequently, institutional review boards (IRBs) are faced with a conundrum—how to reasonably protect patient safety without blunting the effectiveness of protocols that make use of bacterial and toxin methods that can result in sepsis or, in some cases seek, to put subjects into a cytokine storm or septic state and have them recover. These protocols are high risk; thus, this perspective was precipitated by this conundrum. Here we also cite gene therapy trials that appear to be vector-dose-related [2–6] .  \nWe are also informed by an innovative treatment that used injections of live bacteria into gliomas in an attempt to induce remission and to repeat a method first successful on cancer in 1891 [7,8] . That attempt did not succeed. Subjects became septic and died. In the  \nresulting investigation, a survey was done, and, out of some 15 clinicians and scientists questioned not connected with the investigators, neither clinicians working on microbial methods nor scientists performing animal model studies of microbial methods were aware of the SIGLEC-13&17 mechanism discussed here nor its significance. Our group also noted similarities to continuing problems in gene therapy trials in which subjects periodically die.  \nThe principal investigators in the aforementioned innovative treatments had done proper rat experiments, and used that data to guide th","cbCaibvVzFB9Rh7w","https://ap.wps.com/l/cbCaibvVzFB9Rh7w","pdf",1219933,17,"English","# Abstract\n# Introduction\n# Sepsis, Remission in Cancer, and Bacterial Methods","[{\"question\":\"Why do the authors focus on glioblastoma in this perspective?\",\"answer\":\"Glioblastoma is described as highly resistant with low survival and few therapeutic options, making it a central focus for exploring bacterial and toxin-based approaches.\"},{\"question\":\"What guidance does the paper propose for institutional review boards (IRBs)?\",\"answer\":\"It outlines protocols IRBs should consider for live bacterial or synthetic immuno-stimulatory trials, especially to protect patient safety when sepsis or cytokine storm risk exists.\"},{\"question\":\"How do SIGLEC-13\\u002617 and TLR-4 signaling affect interpretation of trial results?\",\"answer\":\"The authors argue that human SIGLEC-13\\u002617 uniquely modulate excessive TLR-4 signaling and that humans are far more sensitive to LPS/endotoxin than mice and rats, affecting how animal model results translate to humans.\"}]","Perspective on Lessons Not Learned: From Coley’s Toxins to Microbial Drug Delivery - Guidance for Institutional Review Boards (IRBs) | PDF",1790083480,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6183f4c6361413c6655b2b2bf5afbb94.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b773bf5247173b913a47e5d81581137b.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/775ded255b2647760f8bd71c3e9f302d.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4f74c129a772ee1e9f743c5be3d6b11.webp",980,1385]